Stocks-Prognosis.com
Search on StockPrognosis.com
To search on the site stockprognosis.com enter the name of the ticker, company name, or search phrase
Sections of the site



Bristol-Myers Squibb continues its impressive dividend streak with a 16th consecutive increase

December 17, 2024
Bristol-Myers Squibb (NYSE:BMY), a leading pharmaceutical company, has announced its 16th consecutive annual increase in dividends. This news comes as a pleasant surprise to shareholders who can now expect a larger payout compared to the previous year. With a dividend rate of 0.62, Bristol-Myers Squibb is committed to providing consistent returns to its investors.

The company's dedication to rewarding its shareholders is evident in its 93-year dividend streak, demonstrating a long-standing commitment to the financial well-being of its investors. This consistent increase in dividends reflects the company's overall success and stability in the market.

Bristol-Myers Squibb has been a reliable player in the pharmaceutical industry, focusing on the development of innovative and life-saving drugs. Its success can be attributed to its strong research and development capabilities, a robust pipeline, and strategic partnerships.

Investors looking to capitalize on this positive news may consider seeking guidance from professionals at Stocks Prognosis. The experts at Stocks Prognosis can provide insights and forecasts on the potential movement of Bristol-Myers Squibb's stock, allowing investors to make informed decisions.

With its impressive dividend streak and commitment to shareholder value, Bristol-Myers Squibb remains a promising investment opportunity for long-term investors.

Find out how the BRISTOL-MYERS SQUIBB COMPANY rate is expected to change

Get Forecast for BMY

Investor opinions & comments:

I'm not convinced that Bristol-Myers Squibb's dividend streak is a true reflection of their success. It could just be a marketing tactic to lure investors
— from EliWells at 12-21-2024 11:51
I've been a long-time investor in Bristol-Myers Squibb, and this consistent increase in dividends only reinforces my confidence in the company
— from AnnaDuncan at 12-21-2024 11:27
I'll believe it when I see it. Dividend increases are great, but I'm skeptical about the overall stability of the pharmaceutical industry
— from MarketMegan at 12-21-2024 10:11
Bristol-Myers Squibb's commitment to providing consistent returns to shareholders is commendable. It shows their dedication to their investors' financial well-being
— from LauraAnderson at 12-20-2024 14:40
I hope this dividend increase is not just a temporary boost to attract investors. It would be disappointing if they can't sustain this growth in the long run
— from CharlotteCampbell at 12-20-2024 11:26
I've been considering investing in healthcare stocks, and this news about Bristol-Myers Squibb's dividend increase has definitely caught my attention
— from GraceStewart at 12-20-2024 09:14
It's impressive to see a company with such a long dividend streak. Bristol-Myers Squibb must be doing something right to consistently reward its shareholders
— from MatthewGarcia at 12-20-2024 04:52
With Bristol-Myers Squibb's successful track record in the pharmaceutical industry, I have confidence that their dividends will continue to grow in the future
— from AdamWells at 12-18-2024 23:59
This is great news for shareholders! I'm excited to see my dividends increase
— from JosephMorris at 12-18-2024 14:41
If you want to leave a comment, then you need Login or Register





Other news for BMY

BMYJune 23, 2025Bristol Myers Squibb NYSE:BMY Set to Revolutionize Cancer Treatment with Breakthrough Drug  ~1 min.

Bristol Myers Squibb Company, a leading pharmaceutical company, is on the verge of revolutionizing cancer treatment with its groundbreaking new drug....

BMYJune 12, 2025BMY: Bristol-Myers Squibb Co. Reports Positive Phase 3 Trial Results For Sotyktu  ~1 min.

Investors are taking notice of Bristol-Myers Squibb Company, as they have recently announced positive phase 3 trial results for their drug Sotyktu. This news has caused BMY shares to rise by 3....

BMYMay 14, 2025QuantWave Successfully Achieves Price Target Forecast for Bristol-Myers Squibb Company with 14.06% Profit  ~2 min.

QuantWave, an automated forecasting platform, recently celebrated a significant achievement in its analytics with the successful price target forecast for the stock of BRISTOL-MYERS SQUIBB COMPANY....

BMYMay 14, 2025BRISTOL-MYERS SQUIBB COMPANY Hits QuantWave Price Target with 13.0% Profit Margin  ~2 min.

On April 11, 2025, QuantWave, an automated forecasting platform, released a short signal for BRISTOL-MYERS SQUIBB COMPANY with a price target forecast of 44.12 $, indicating a 13....

BMYMay 8, 2025BRISTOL-MYERS SQUIBB COMPANY Hits Price Target as QuantWave Forecast Achieves 7.55% Profit  ~1 min.

BRISTOL-MYERS SQUIBB COMPANY has seen its stock reach the predicted price target set by QuantWave's automated forecasting platform....



Related news

REGNJanuary 4, 2025Regeneron Pharmaceuticals Inc.: A Strong Investment Opportunity for Shareholders  ~1 min.

Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) has proven to be a successful investment option for shareholders, with a decent 89% return over the last five years....

ABTNovember 30, 2024Abbott Laboratories Expanding Global Presence with Strategic Partnerships  ~2 min.

Abbott Laboratories (NYSE: ABT) continues to solidify its position as a global leader in healthcare through strategic partnerships with top institutions and organizations....

REGNJanuary 8, 2025Regeneron Pharmaceuticals Sets Q4 and Full Year 2024 Earnings Release for February 4  ~2 min.

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) announced today that it will release its financial and operating results for the fourth quarter and full year 2024 on February 4, 2025....

REGNJanuary 1, 2025Regeneron Pharmaceuticals Inc. Shows Impressive Growth and Promising Future  ~2 min.

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) has been making significant strides in the healthcare sector, and investors have reaped the benefits....

REGNJanuary 12, 2025Regeneron Pharmaceuticals Faces Shareholder Class Action Lawsuit  ~1 min.

Regeneron Pharmaceuticals, Inc., a leading biotechnology company, is currently facing a shareholder class action lawsuit....